Edition:
India

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

2.01USD
1:30am IST
Change (% chg)

$0.03 (+1.52%)
Prev Close
$1.98
Open
$2.00
Day's High
$2.02
Day's Low
$1.90
Volume
145,866
Avg. Vol
151,769
52-wk High
$9.19
52-wk Low
$1.56

Latest Key Developments (Source: Significant Developments)

Akari QTRLY Loss Per Share $0.00
Wednesday, 24 Apr 2019 

April 23 (Reuters) - Akari Therapeutics PLC ::AKARI REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AKARI THERAPEUTICS PLC QTRLY LOSS PER SHARE $0.00.AKARI THERAPEUTICS PLC - AS OF DECEMBER 31, 2018, COMPANY HAD CASH OF $5.4 MILLION, AS COMPARED TO CASH OF $28.1 MILLION AS OF DECEMBER 31, 2017.  Full Article

Positive FDA Meeting Outlines Path Ahead For Akari Therapeutics’S Coversin In Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (Hsct-Tma)
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Akari Therapeutics PLC ::POSITIVE FDA MEETING OUTLINES PATH AHEAD FOR AKARI THERAPEUTICS’S COVERSIN IN HEMATOPOIETIC STEM CELL TRANSPLANT-RELATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA).AKARI THERAPEUTICS PLC - HSCT-TMA TRIAL IN PEDIATRIC PATIENTS EXPECTED TO START Q4 2019 FOLLOWING RECENT FDA FEEDBACK.AKARI THERAPEUTICS PLC - HSCT-TMA TRIAL IN PEDIATRIC PATIENTS EXPECTED TO START Q4 2019 FOLLOWING RECENT FDA FEEDBACK.AKARI THERAPEUTICS PLC - FRAMEWORK FOR TRIAL DESIGN WAS AGREED TO WITH FDA.AKARI THERAPEUTICS PLC -AKARI PLANS TO COMMENCE A TRIAL IN EUROPEAN AND U.S. PEDIATRIC HSCT-TMA PATIENTS IN Q4 OF 2019.  Full Article

Akari Qtrly Loss Per Common Share $0.01
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Akari Therapeutics PLC ::AKARI ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AKARI THERAPEUTICS PLC QTRLY LOSS PER COMMON SHARE $0.01.AKARI THERAPEUTICS - AS OF JUNE 30, 2018, HAD CASH OF $15.1 MILLION, AS COMPARED TO CASH OF $28.1 MILLION AS OF DEC 31, 2017.  Full Article

Akari Therapeutics Qtrly Loss Per Common Share $0.01
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Akari Therapeutics Plc ::AKARI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS.AKARI THERAPEUTICS PLC - CAPSTONE, PHASE III NAÏVE PNH TRIAL EXPECTED TO OPEN IN Q1 2018.AKARI THERAPEUTICS - BASED ON CURRENT CASH POSITION AND OPERATING PLAN, EXPECTS HAS SUFFICIENT CASH TO FUND OPERATIONS INTO Q2 2019.AKARI THERAPEUTICS PLC - AS OF DECEMBER 31, 2017, COMPANY HAD CASH AND CASH EQUIVALENTS OF $28.1 MILLION.AKARI THERAPEUTICS PLC - QTRLY LOSS PER COMMON SHARE $0.01.  Full Article

Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful
Saturday, 9 Dec 2017 

Dec 8 (Reuters) - Akari Therapeutics Plc ::AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT.AKARI THERAPEUTICS PLC - NEW DOSING REGIMEN AT 45 MG PER DAY IS EXPECTED TO BE USED IN PHASE III TRIALS.AKARI - PLANS TO COMMENCE TWO PHASE III PNH CLINICAL TRIALS WITH COVERSIN BEGINNING WITH CAPSTONE IN Q1 OF 2018.AKARI THERAPEUTICS PLC - ON TRACK TO PROGRESS INTO PHASE III CLINICAL TRIALS IN Q1 OF 2018.AKARI THERAPEUTICS PLC - SECOND PHASE III TRIAL, ASSET, IS PLANNED FOR H2 2018 & WILL INCLUDE SOLIRIS SWITCH PATIENTS.  Full Article

Akari Therapeutics says priced public offering of american depositary shares
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Akari Therapeutics Plc :Akari therapeutics announces pricing of public offering of american depositary shares.Akari therapeutics plc - priced public offering of 3.5 million american depositary shares, or adss, at $5.00 per ads​.  Full Article